Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5903
    -0.0003 (-0.05%)
     

  • NZD/EUR

    0.5526
    -0.0019 (-0.34%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    82.48
    -0.25 (-0.30%)
     

  • GOLD

    2,396.40
    -1.60 (-0.07%)
     

  • NASDAQ

    17,291.27
    -103.05 (-0.59%)
     

  • FTSE

    7,833.15
    -43.90 (-0.56%)
     

  • Dow Jones

    37,875.88
    +100.50 (+0.27%)
     

  • DAX

    17,714.98
    -122.42 (-0.69%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.1700
    -0.0840 (-0.09%)
     

Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?

Zacks Equity Research
Updated
Mutual Fund Report for TRMCX

Investors focused on the Medical space have likely heard of Pfizer (PFE), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PFE and the rest of the Medical group's stocks.

Pfizer is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. PFE is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for PFE's full-year earnings has moved 0.09% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

ADVERTISEMENT

Our latest available data shows that PFE has returned about 2.73% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.84% on average. This means that Pfizer is outperforming the sector as a whole this year.

Looking more specifically, PFE belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #197 in the Zacks Industry Rank. On average, this group has lost an average of 0.46% so far this year, meaning that PFE is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track PFE. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.